Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models

Dysregulation of hepatic lipid and cholesterol metabolism is a significant contributor to cardiometabolic health, resulting in excessive liver lipid accumulation and ultimately non-alcoholic steatohepatitis (NASH). Therapeutic activators of the AMP-Activated Protein Kinase (AMPK) have been proposed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EBioMedicine
Main Authors: Esquejo, Ryan M., Salatto, Christopher T., Delmore, Jake, Albuquerque, Bina, Reyes, Allan, Shi, Yuji, Moccia, Rob, Cokorinos, Emily, Peloquin, Matthew, Monetti, Mara, Barricklow, Jason, Bollinger, Eliza, Smith, Brennan K., Day, Emily A., Nguyen, Chuong, Geoghegan, Kieran F., Kreeger, John M., Opsahl, Alan, Ward, Jessica, Kalgutkar, Amit S., Tess, David, Butler, Lynne, Shirai, Norimitsu, Osborne, Timothy F., Steinberg, Gregory R., Birnbaum, Morris J., Cameron, Kimberly O., Miller, Russell A.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6014578/
https://ncbi.nlm.nih.gov/pubmed/29673898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2018.04.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados